IV credibility shot! Just 4 weeks ago reaffirmed guidance TWICE on investor webinar. The shortfall to full year guidance must have been obvious at that stage with H1 being so low relative to full year guidance. Now he won't provide any revenue guidance at all! How can he calculate guide positive EBITDA and cash flow without establishing revenue level. Accounting 101!
Ann: Next Science revises FY24 guidance, page-3
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NXS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.030(15.8%) |
Mkt cap ! $64.27M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 22.0¢ | 19.0¢ | $29.19K | 135.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 80000 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 28990 | 2 |
View Market Depth
| Last trade - 15.15pm 01/10/2024 (20 minute delay) ? |
| NXS (ASX) Chart |